Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Transamination. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN109293569B reveals solvent-free transamination using DMF. Achieve high-purity pharmaceutical intermediates with significant cost reduction and simplified supply chains.
Patent CN109293569A enables solvent-free formamide synthesis. Reduces cost and improves supply chain reliability for pharmaceutical intermediates manufacturing globally.
Patent CN118726300A reveals a novel transaminase mutant for producing agrochemical intermediates with high optical purity and reduced manufacturing costs.
Novel aminotransferase patent enables high-purity sitagliptin intermediate production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN106754806B discloses a high-efficiency transaminase for synthesizing (R)-3-aminobutanol, offering superior substrate tolerance and eliminating organic cosolvents for cost-effective manufacturing.
Patent CN106111189B reveals a novel chiral pyridoxamine catalyst enabling mild synthesis of alpha-amino acids with high ee values and scalable manufacturing potential.
Patent CN113789310B reveals high-yield transaminase route for moxifloxacin intermediates, eliminating DMSO for cost-effective and scalable API manufacturing.
Patent CN102766058A details a novel organocatalytic route for photoactive alpha-amino acids, offering cost reduction in API manufacturing and reliable supply chain solutions.
Patent CN106497843B reveals high-purity biocatalytic route. Reduces costs and enhances supply chain reliability for diabetes drug intermediates.
Novel enzymatic route for Sitagliptin key intermediate reduces costs and eliminates heavy metals. Ideal for reliable pharmaceutical intermediate suppliers seeking scalable API manufacturing solutions.
Patent CN106916857B reveals a three-enzyme system for high-purity L-glufosinate-ammonium. This breakthrough enables significant cost reduction and supply chain reliability.
Novel enzymatic route for tofacitinib intermediate offers high purity and yield. Reduces cost and waste for pharmaceutical manufacturing supply chains.
Patent CN103014081A details a green enzymatic route for 3-amino-4-(2,4,5-trifluorophenyl)methyl butyrate, offering superior chirality and cost reduction in pharmaceutical intermediate manufacturing.
Novel enzymatic route for (S,S)-2,8-diazabicyclo[4,3,0]nonane. Reduces steps, avoids high-pressure hydrogenation. Reliable pharma intermediate supplier.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediate synthesis, offering superior conversion rates and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN1095830C details a novel amine exchange method for producing fungicide intermediates, offering improved safety and industrial scalability for agrochemical manufacturers.
Novel enzymatic synthesis route ensures high purity and yield for HIV integrase inhibitor intermediates, offering significant supply chain stability and cost efficiency for global pharmaceutical manufacturers.
Patent CN112930348A details an enzymatic route for Safraninib, improving yield and reducing waste compared to chiral resolution methods.
Patent CN113292495B details a high-yield synthesis of (S)-amino benazepril intermediate using quinine-derived catalysis, offering significant cost and safety advantages for API manufacturing.